Search Within

Harper Hubbeling

Formats
  1. Meeting Abstract (36)
  2. Journal Article (8)
  3. Research Letter (1)
Groups
  1. GME, Radiation Oncology (45)
  2. Graduate Medical Education (45)
  3. Radiation Oncology, Department of (43)
  4. Survivorship Research (39)
  5. Department of Medicine (32)
  6. Hematologic Malignancies, Division of (27)

More Groups

People
  1. Brandon Imber (41)
  2. Joachim Yahalom (35)
  3. Carla Hajj (33)
  4. Kathryn Tringale (28)
  5. Beatrice Fregonese (21)
  6. Michael Scordo (19)

More People

Years
  1. 2024 (3)
  2. 2023 (19)
  3. 2022 (18)
  4. 2021 (4)
  5. 2019 (1)
Publications
  1. Blood (13)
  2. International Journal of Radiation Oncology, Biology, Physics (8)
  3. Hematological Oncology (7)
  4. Radiotherapy and Oncology (4)
  5. Clinical Cancer Research (3)
  6. Transplantation and Cellular Therapy (3)

More Publications

Publishers
  1. Elsevier Inc. (15)
  2. American Society of Hematology (14)
  3. Wiley Blackwell (7)
  4. American Association for Cancer Research (3)
  5. American Medical Association (1)
  6. American Society of Clinical Oncology (1)

More Publishers

Results (45)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Outcomes with local therapy and tyrosine kinase inhibition in patients with ALK/ROS1/RET-rearranged lung cancers
    Meeting Abstract

    Hubbeling, H. G.; Choudhury, N.; Falcon, C.; Rusch, V. W.; Park, B.; Ziv, E.; Shaverdian, N.; Gelblum, D.; Shepherd, A. F.; Simone, C. B. 2nd; more...
    International Journal of Radiation Oncology, Biology, Physics (2021)

    Fulltext@MSK | Save
  • Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion–positive lung cancer
    Journal Article

    Lin, J. J.; Choudhury, N. J.; Yoda, S.; Zhu, V. W.; Johnson, T. W.; Sakhtemani, R.; Dagogo-Jack, I.; Digumarthy, S. R.; Lee, C.; Do, A.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Treatment with next-generation ALK inhibitors fuels plasma ALK mutation diversity
    Journal Article

    Dagogo-Jack, I.; Rooney, M.; Lin, J. J.; Nagy, R. J.; Yeap, B. Y.; Hubbeling, H.; Chin, E.; Ackil, J.; Farago, A. F.; Hata, A. N.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save